Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET Predicting Response to Fulvestrant in ER+ Metastatic Breast Cancer
NCT03507088Completed
- Sponsor
- Zhimin Shao
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluoroestradiol f 18 in breast cancer, sponsored by Zhimin Shao. Primary endpoint: Accuracy of the change of FES uptake in predicting progression-free survival at 28 days. Started Sep 2015; status: completed.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03507088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507088.